Response Genetics (OTCPK:RGDX.Q) - Stock Price, News & Analysis

RGDX.Q Stock Overview

A life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. More details

RGDX.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($38)

Latest financial reports are more than a year old

Response Genetics, Inc Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

MJ Holdings

OTCPK:MJNE

US$58.0

Price History & Performance

Summary of all time highs, changes and price drops for Response Genetics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.00%
5 Year Change	-99.97%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	RGDX.Q	US Life Sciences	US Market
7D	0%	3.9%	1.6%
1Y	n/a	4.7%	32.3%

Return vs Industry: Insufficient data to determine how RGDX.Q performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how RGDX.Q performed against the US Market.

Price Volatility

Is RGDX.Q's price volatile compared to industry and market?
RGDX.Q volatility
RGDX.Q Average Weekly Movement	n/a
Life Sciences Industry Average Movement	8.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: RGDX.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RGDX.Q's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	n/a	www.responsegenetics.com

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites.

Response Genetics, Inc Fundamentals Summary

How do Response Genetics's earnings and revenue compare to its market cap?
RGDX.Q fundamental statistics
Market cap	US$38.00
Earnings (TTM)	-US$14.21m
Revenue (TTM)	US$16.62m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is RGDX.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGDX.Q income statement (TTM)
Revenue	US$16.62m
Cost of Revenue	US$10.37m
Gross Profit	US$6.25m
Other Expenses	US$20.46m
Earnings	-US$14.21m

Last Reported Earnings

Mar 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did RGDX.Q perform over the long term?

See historical performance and comparison